These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9120003)

  • 1. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.
    Sands MS; Vogler C; Torrey A; Levy B; Gwynn B; Grubb J; Sly WS; Birkenmeier EH
    J Clin Invest; 1997 Apr; 99(7):1596-605. PubMed ID: 9120003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy for murine mucopolysaccharidosis type VII.
    Sands MS; Vogler C; Kyle JW; Grubb JH; Levy B; Galvin N; Sly WS; Birkenmeier EH
    J Clin Invest; 1994 Jun; 93(6):2324-31. PubMed ID: 8200966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
    Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
    Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates.
    Sands MS; Barker JE; Vogler C; Levy B; Gwynn B; Galvin N; Sly WS; Birkenmeier E
    Lab Invest; 1993 Jun; 68(6):676-86. PubMed ID: 8515654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.
    Vogler C; Levy B; Galvin NJ; Thorpe C; Sands MS; Barker JE; Baty J; Birkenmeier EH; Sly WS
    Pediatr Res; 1999 Jun; 45(6):838-44. PubMed ID: 10367775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
    Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
    J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.
    O'Connor LH; Erway LC; Vogler CA; Sly WS; Nicholes A; Grubb J; Holmberg SW; Levy B; Sands MS
    J Clin Invest; 1998 Apr; 101(7):1394-400. PubMed ID: 9525982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII.
    Freeman BJ; Roberts MS; Vogler CA; Nicholes A; Hofling AA; Sands MS
    Blood; 1999 Sep; 94(6):2142-50. PubMed ID: 10477745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses.
    Soper BW; Pung AW; Vogler CA; Grubb JH; Sly WS; Barker JE
    Pediatr Res; 1999 Feb; 45(2):180-6. PubMed ID: 10022587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII.
    Sands MS; Erway LC; Vogler C; Sly WS; Birkenmeier EH
    Blood; 1995 Sep; 86(5):2033-40. PubMed ID: 7655032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation.
    Ohlemiller KK; Vogler CA; Roberts M; Galvin N; Sands MS
    Exp Eye Res; 2000 Nov; 71(5):469-81. PubMed ID: 11040082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice.
    Poorthuis BJ; Romme AE; Willemsen R; Wagemaker G
    Pediatr Res; 1994 Aug; 36(2):187-93. PubMed ID: 7970933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In utero fetal liver cell transplantation without toxic irradiation alleviates lysosomal storage in mice with mucopolysaccharidosis type VII.
    Barker JE; Deveau S; Lessard M; Hamblen N; Vogler C; Levy B
    Blood Cells Mol Dis; 2001; 27(5):861-73. PubMed ID: 11783949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse.
    Vogler C; Sands M; Higgins A; Levy B; Grubb J; Birkenmeier EH; Sly WS
    Pediatr Res; 1993 Dec; 34(6):837-40. PubMed ID: 8108204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells.
    Ross CJ; Bastedo L; Maier SA; Sands MS; Chang PL
    Hum Gene Ther; 2000 Oct; 11(15):2117-27. PubMed ID: 11044913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine mucopolysaccharidosis VIL: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease.
    Vogler C; Barker J; Sands MS; Levy B; Galvin N; Sly WS
    Pediatr Dev Pathol; 2001; 4(5):421-33. PubMed ID: 11779044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.
    Rowan DJ; Tomatsu S; Grubb JH; Haupt B; Montaño AM; Oikawa H; Sosa AC; Chen A; Sly WS
    Mol Genet Metab; 2012 Sep; 107(1-2):161-72. PubMed ID: 22902520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.
    Vogler C; Levy B; Grubb JH; Galvin N; Tan Y; Kakkis E; Pavloff N; Sly WS
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14777-82. PubMed ID: 16162667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice.
    Sakurai K; Iizuka S; Shen JS; Meng XL; Mori T; Umezawa A; Ohashi T; Eto Y
    Gene Ther; 2004 Oct; 11(19):1475-81. PubMed ID: 15295619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts.
    Moullier P; Bohl D; Heard JM; Danos O
    Nat Genet; 1993 Jun; 4(2):154-9. PubMed ID: 8348154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.